Caristo Diagnostics news and updates

Every material change AI Health Index has tracked at Caristo Diagnostics: new modules, model and architecture updates, clinical evidence, regulatory status, security certifications, and integration depth. Each entry states what changed, cites its source, and carries our read on what it means for a buyer. The graded assessment of this vendor across all fifteen capability axes sits on its index profile.

Funding rounds, valuations, and awards are not product changes and are not logged here. Acquisitions appear only where there is direct product impact.

Follow this change log by RSS

Free for your reader, newsletter or automation tool. One feed covers the whole index, and every category has its own.

All feeds and terms
Impact
Type
2 entries
Showing changes for Caristo Diagnostics only.Show the full log

November 2026

C
Caristo Diagnostics
Nov 11, 2026
HighVerified
Clinical evidence

JAMA Cardiology published a University of Oxford led study validating CaRi-Heart FAI-Score coronary inflammation measurement from routine CCTA in 19,110 patients. Very high coronary inflammation in patients with a calcium score of zero was associated with a 14.1x higher risk of cardiovascular death, and 10.4x higher risk in patients without calcified or noncalcified plaque. Among CAC zero patients who later died of cardiovascular causes, FAI-Score reclassified nearly half as high or very high risk.

Our read

Gives cardiology and imaging buyers peer reviewed outcome data showing the recently FDA authorized CaRi-Heart adds prognostic value beyond calcium scoring and plaque analysis, which supports the case for adopting it on existing CCTA workflows. The noncontrast CT application described in the same study is investigational and not a shipped capability.

Related axis: Clinical and Operational EvidenceVendor announcementView source

July 2026

C
Caristo Diagnostics
Jul 29, 2026
HighVerified
Regulatory / FDA

The FDA granted De Novo authorization (DEN250042) for CaRi-Heart, which quantifies coronary inflammation from routine coronary CT angiography and estimates a 10 year cardiovascular mortality risk. Caristo announced it on 29 July and plans a US commercial launch in the third quarter, expanding through the fourth. It joins CaRi-Plaque, cleared in February 2025, so plaque and inflammation can be read from one scan.

Our read

Until July, CaRi-Heart was limited to investigational use in the US. The company has not yet published the US indication or any conditions attached to the authorization, so ask for both before using the risk estimate in care. Category III CPT codes 0992T and 0993T, effective 1 January 2026, give practices a way to code it.

Related axis: FDA and Regulatory StatusVendor announcementView source

What has changed at Caristo Diagnostics recently?

The most recent change AI Health Index logged at Caristo Diagnostics is dated Nov 11, 2026. JAMA Cardiology published a University of Oxford led study validating CaRi-Heart FAI-Score coronary inflammation measurement from routine CCTA in 19,110 patients. It is one of 2 dated, sourced entries the index holds for Caristo Diagnostics.